181 related articles for article (PubMed ID: 29219214)
21. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
[TBL] [Abstract][Full Text] [Related]
22. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
23. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
24. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
25. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Agrawal N; Jiao Y; Sausen M; Leary R; Bettegowda C; Roberts NJ; Bhan S; Ho AS; Khan Z; Bishop J; Westra WH; Wood LD; Hruban RH; Tufano RP; Robinson B; Dralle H; Toledo SP; Toledo RA; Morris LG; Ghossein RA; Fagin JA; Chan TA; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Nelkin BD; Ball DW
J Clin Endocrinol Metab; 2013 Feb; 98(2):E364-9. PubMed ID: 23264394
[TBL] [Abstract][Full Text] [Related]
26. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
[TBL] [Abstract][Full Text] [Related]
27. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
28. RET codon 609 mutations: a contribution for better clinical managing.
Mian C; Sartorato P; Barollo S; Zane M; Opocher G
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703
[TBL] [Abstract][Full Text] [Related]
29. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
30. A primer on the genetics of medullary thyroid cancer.
Larouche V; Akirov A; Thomas CM; Krzyzanowska MK; Ezzat S
Curr Oncol; 2019 Dec; 26(6):389-394. PubMed ID: 31896937
[TBL] [Abstract][Full Text] [Related]
31. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
32. A Novel Germline Deletion of p.C630 in RET Causes MTC and Promotes Cell Proliferation and Sensitivity to Pralsetinib.
Ma X; Ma X; Chin L; Zhu Z; Han H
J Clin Endocrinol Metab; 2022 Aug; 107(9):2636-2643. PubMed ID: 35689816
[TBL] [Abstract][Full Text] [Related]
33. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
[TBL] [Abstract][Full Text] [Related]
34. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
35. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.
Figlioli G; Landi S; Romei C; Elisei R; Gemignani F
Mutat Res; 2013; 752(1):36-44. PubMed ID: 23059849
[TBL] [Abstract][Full Text] [Related]
36. Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.
Qi XP; Ying RB; Ma JM; Liu WT; Du ZF; Fei J; Yang CP; Song QZ; Jin HY; Chen ZG; Han JS; Wang JQ; Chen XL; Zhao Y; Lu JJ; Zhang XN
Fam Cancer; 2012 Mar; 11(1):131-6. PubMed ID: 22068382
[TBL] [Abstract][Full Text] [Related]
37. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
38. p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.
Loveday C; Josephs K; Chubb D; Gunning A; Izatt L; Tischkowitz M; Ellard S; Turnbull C
J Clin Endocrinol Metab; 2018 Nov; 103(11):4275-4282. PubMed ID: 29590403
[TBL] [Abstract][Full Text] [Related]
39. Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.
Masbi MH; Mohammadiasl J; Galehdari H; Ahmadzadeh A; Tabatabaiefar MA; Golchin N; Haghpanah V; Rahim F
Asian Pac J Cancer Prev; 2014; 15(5):2027-33. PubMed ID: 24716929
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA; Hatakana R; Lourenço DM; Lindsey SC; Camacho CP; Almeida M; Lima JV; Sekiya T; Garralda E; Naslavsky MS; Yamamoto GL; Lazar M; Meirelles O; Sobreira TJ; Lebrao ML; Duarte YA; Blangero J; Zatz M; Cerutti JM; Maciel RM; Toledo SP
Endocr Relat Cancer; 2015 Feb; 22(1):65-76. PubMed ID: 25425582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
